$18.78 -0.19 (%) Supernus Pharmaceuticals Inc - NASDAQ

May. 26, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Benzinga's Top Upgrades

    Benzinga | Feb. 8, 2016 | 08:55AM EST
  2. 16 Stocks Moving In Friday's After-Hours Session

    Benzinga | Dec. 11, 2015 | 17:03PM EST
  3. Supernus Announces FDA Acceptance of sNDA to Add Migraine to Trokendi XR Label

    Benzinga | Oct. 22, 2015 | 18:39PM EST
  4. Fitbit Keeps Up Pace As Stocks Remain Near Session Highs

    IBD | Jun. 18, 2015 | 14:34PM EST
  5. Benzinga's Top Upgrades

    Benzinga | Jun. 18, 2015 | 09:10AM EST
  6. Jefferies Upgrades Supernus Pharmaceuticals To Buy

    Benzinga | Jun. 18, 2015 | 07:55AM EST
  7. Benzinga's Top Initiations

    Benzinga | Jun. 12, 2015 | 09:19AM EST
  8. Horizon Pharma Up On Bullish Leerink Initiation

    IBD | May. 22, 2015 | 11:39AM EST
  9. Robert Bruce new Buys

    GuruFocus | Feb. 16, 2015 | 10:44AM EST
  10. Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR

    Benzinga | Dec. 10, 2014 | 07:30AM EST
  11. Supernus Reports Issuance of Fifth US Patent Protecting Trokendi XR(R)

    Benzinga | Nov. 24, 2014 | 07:33AM EST
  12. Third Quarter Was Robert Bruce's Busiest in 2014

    GuruFocus | Nov. 21, 2014 | 17:09PM EST
  13. Earnings Scheduled For November 11, 2014

    Benzinga | Nov. 11, 2014 | 04:56AM EST
  14. Supernus Offers Business Update: Reaffirms Does Not Need Added Capital, Will 'Explore a Broad Range of Strategic Opportunities'

    Benzinga | Sep. 22, 2014 | 16:16PM EST
  15. Morning Market Movers

    Benzinga | Aug. 12, 2014 | 09:42AM EST
  16. Earnings Scheduled For March 12, 2014

    Benzinga | Mar. 12, 2014 | 05:09AM EST
  17. Supernus Pharma Announces Data from Phase III PROSPER Study on Oxtellar XR Showed Potential Boost to Tolerability

    Benzinga | Feb. 3, 2014 | 07:32AM EST
  18. Stocks Hitting 52-Week Highs

    Benzinga | Jan. 27, 2014 | 10:54AM EST
  19. Morning Market Movers

    Benzinga | Dec. 24, 2013 | 09:59AM EST
  20. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 24, 2013 | 08:09AM EST
  21. Stocks To Watch For December 24, 2013

    Benzinga | Dec. 24, 2013 | 04:13AM EST
  22. Merger Monday Lives Up To Its Name: 33.175 Billion In Deals

    Benzinga | Dec. 16, 2013 | 15:41PM EST
  23. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 19, 2013 | 08:11AM EST
  24. Supernus Pharma Reports Final FDA Approval, Expected Upcoming Launch of Trokendi XR

    Benzinga | Aug. 19, 2013 | 07:34AM EST
  25. Supernus Prices 6M Share Public Offering at $8/Share

    Benzinga | Nov. 29, 2012 | 23:16PM EST
  26. Supernus Pharmaceuticals Reports Positive Phase IIb Results on SPN-810 for Treatment of Impulsive Aggression in ADHD Patients

    Benzinga | Nov. 20, 2012 | 14:43PM EST
  27. UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Supernus Pharmaceuticals

    Benzinga | Aug. 13, 2012 | 06:19AM EST
  28. Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer

    Benzinga | Jul. 20, 2012 | 02:01AM EST
  29. Jim Cramer Says Take Profits on Synacor and Supernus Pharmaceuticals

    Benzinga | Jul. 19, 2012 | 12:28PM EST
  30. Supernus Pharma Pops 25% on Tentative FDA Approval

    Benzinga | Jul. 6, 2012 | 08:22AM EST
  31. Supernus Pharmaceuticals Down Nearly 10%

    Benzinga | Jun. 28, 2012 | 05:02AM EST
  32. Three Tech IPOs Seek To Break The Facebook Curse

    IBD | Jun. 26, 2012 | 06:43AM EST
  33. Supernus Pharmaceuticals Skyrockets on FDA Approval

    Benzinga | Jun. 26, 2012 | 06:13AM EST
  34. Stocks Hitting 52-Week Highs

    Benzinga | Jun. 26, 2012 | 04:01AM EST
  35. Morning Market Movers

    Benzinga | Jun. 26, 2012 | 03:48AM EST
  36. Benzinga's Top Pre-Market Gainers

    Benzinga | Jun. 26, 2012 | 02:17AM EST
  37. UPDATE: Citi Initiates Coverage on Supernus Pharmaceuticals

    Benzinga | May. 29, 2012 | 02:46AM EST
  38. Piper Jaffray Initiates Coverage on Supernus Pharmaceuticals

    Benzinga | May. 29, 2012 | 02:17AM EST
Trading Center